Abstract
Diabetes, is a metabolic disorder characterised by chronic hyperglycaemia, hypertension, dyslipidaemia, microalbuminuria and inflammation. Moreover, there are a number of complications associated with this condition including retinopathy, neuropathy and nephropathy. Diabetic nephropathy, is the major cause of end-stage renal disease in Western societies affecting a substantial proportion (25-40%) of patients with diabetes. Advanced glycation end products (AGEs) have been identified as important modulators of the development and progression of diabetic nephropathy, through both receptor dependant and independent interactions. AGEs elicit their receptor mediated effects via their engagement with numerous receptors and binding proteins which are broadly thought to be either inflammatory (RAGE and AGE-R2) or clearance receptors (AGE-R1, AGE-R3, CD36, Scr-II, FEEL-1 and FEEL-2). Modulation of AGE receptor expression is an important potential therapeutic approach worth consideration as a treatment for diabetic nephropathy and likely applicable to other vascular complications.
Keywords: Advanced glycation end-products (AGEs), diabetic nephropathy, modulation of AGE-receptors, RAGE, AGE-R1, soluble-RAGE
Current Drug Targets
Title: Interactions Between Advanced Glycation End-Products (AGE) and their Receptors in the Development and Progression of Diabetic Nephropathy – are these Receptors Valid Therapeutic Targets
Volume: 10 Issue: 1
Author(s): Karly C. Sourris and Josephine M. Forbes
Affiliation:
Keywords: Advanced glycation end-products (AGEs), diabetic nephropathy, modulation of AGE-receptors, RAGE, AGE-R1, soluble-RAGE
Abstract: Diabetes, is a metabolic disorder characterised by chronic hyperglycaemia, hypertension, dyslipidaemia, microalbuminuria and inflammation. Moreover, there are a number of complications associated with this condition including retinopathy, neuropathy and nephropathy. Diabetic nephropathy, is the major cause of end-stage renal disease in Western societies affecting a substantial proportion (25-40%) of patients with diabetes. Advanced glycation end products (AGEs) have been identified as important modulators of the development and progression of diabetic nephropathy, through both receptor dependant and independent interactions. AGEs elicit their receptor mediated effects via their engagement with numerous receptors and binding proteins which are broadly thought to be either inflammatory (RAGE and AGE-R2) or clearance receptors (AGE-R1, AGE-R3, CD36, Scr-II, FEEL-1 and FEEL-2). Modulation of AGE receptor expression is an important potential therapeutic approach worth consideration as a treatment for diabetic nephropathy and likely applicable to other vascular complications.
Export Options
About this article
Cite this article as:
Sourris C. Karly and Forbes M. Josephine, Interactions Between Advanced Glycation End-Products (AGE) and their Receptors in the Development and Progression of Diabetic Nephropathy – are these Receptors Valid Therapeutic Targets, Current Drug Targets 2009; 10 (1) . https://dx.doi.org/10.2174/138945009787122905
DOI https://dx.doi.org/10.2174/138945009787122905 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Beneficial Effects of Traditional Chinese Medicine on the Treatment of Osteoporosis on Ovariectomised Rat Models
Current Drug Targets Study of Irisin Hormone Level in Type 2 Diabetic Patients and Patients with Diabetic Nephropathy
Current Diabetes Reviews Hypertension and Diabetes: Emphasis on the Renin-Angiotensin System in Atherosclerosis
Current Hypertension Reviews The Anti-Atherogenic Effects of Thiazolidinediones
Current Diabetes Reviews Exploring Newer Target Sodium Glucose Transporter 2 for the Treatment of Diabetes Mellitus
Mini-Reviews in Medicinal Chemistry Preconception Care for the Type 2 Diabetic Mother: A Review on Current Care Guidelines
Current Women`s Health Reviews The Interaction Between Gender and Diabetes Mellitus in the Coronary Heart Disease Risk
Current Pharmaceutical Design The Role of Statins in Preventing the Progression of Congestive Heart Failure in Patients with Metabolic Syndrome
Current Pharmaceutical Design Dysregulation of SIRT-1 Signaling in Multiple Sclerosis and Neuroimmune Disorders: A Systematic Review of SIRTUIN Activators as Potential Immunomodulators and their Influences on other Dysfunctions
Endocrine, Metabolic & Immune Disorders - Drug Targets Pomegranate, its Components, and Modern Deliverable Formulations as Potential Botanicals in the Prevention and Treatment of Various Cancers
Current Drug Delivery Editorial [Hot topic: Vitamin D Deficiency in Cardiovascular and Renal Disease: New Light Shed on an Old Enemy (Guest Editor: Martin H. de Borst)]
Current Drug Targets Improving Antihypertensive Agent Selection to Promote Nephroprotection
Current Hypertension Reviews Distinct Biomarkers for Early Diagnosis of Diabetic Nephropathy
Current Diabetes Reviews Green Tea Attenuates Cardiovascular Remodeling and Metabolic Symptoms in High Carbohydrate-Fed Rats
Current Pharmaceutical Biotechnology Metalloproteinases and Metalloproteinase Inhibitors in Age-Related Diseases
Current Pharmaceutical Design Addressing Unmet Medical Needs in Type 1 Diabetes: A Review of Drugs Under Development
Current Diabetes Reviews T-cell Activation Induces Dynamic Changes in miRNA Expression Patterns in CD4 and CD8 T-cell Subsets
MicroRNA Preface
Current Molecular Medicine Lithium and Kidney, 60 Years Later
Current Drug Safety Chromium-Picolinate Therapy in Diabetes Care: Individual Outcomes Require New Guidelines and Navigation by Predictive Diagnostics
Infectious Disorders - Drug Targets